High-Throughput Alternative Splicing Detection In Patients With Non-Small Cell Lung Cancer Treated By Bevacizumab/erlotinib

被引：0
作者：
Baty, F. [1 ]
Brutsche, M. [1 ]
机构：
[1] Cantonal Hosp St Gallen, St Gallen, Switzerland
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3476
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Functional Mechanism of GLDC Gene Alternative Splicing in Non-Small Cell Lung Cancer
    Yuan, Y.
    Ma, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S518 - S518
  • [42] Efficacy and Safety Evaluations of Anlotinib in Patients with Advanced Non-small Cell Lung Cancer Treated with Bevacizumab
    Jiang, F.
    Li, J.
    Kong, X.
    Qu, H.
    Sun, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S436 - S436
  • [43] EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
    Baty, Florent
    Rothschild, Sacha
    Frueh, Martin
    Betticher, Daniel
    Droege, Cornelia
    Cathomas, Richard
    Rauch, Daniel
    Gautschi, Oliver
    Bubendorf, Lukas
    Crowe, Susanne
    Zappa, Francesco
    Pless, Miklos
    Brutsche, Martin
    PLOS ONE, 2013, 8 (09):
  • [44] The presence of EGFR mutations predicts the response in Chinese non-small cell lung cancer patients treated with erlotinib
    Li, Rui-chao
    Zheng, Li-jun
    Fang, Ming-hao
    Yu, Shi-ying
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2014, 29 (02) : E112 - E119
  • [45] Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.
    Fidler, M. J.
    Argiris, A.
    Patel, J. D.
    Johnson, D. H.
    Sandler, A.
    Villaflor, V.
    Coon, J.
    Buckingham, L.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 407S - 407S
  • [46] Prognostic model to predict outcomes in non-small cell lung cancer patients treated with erlotinib as a salvage treatment
    Kim, S.
    Lee, J.
    Park, Y.
    Park, J.
    Ahn, J.
    Im, Y.
    Kang, W.
    Park, K.
    Ahn, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 546 - 546
  • [47] C-erbB-3 Expression in Non-small Cell Lung Cancer (NSCLC) Patients Treated by Erlotinib
    Cstoth, Ingrid
    Anthoine, Geraldine
    Berghmans, Thierry
    Mascaux, Celine
    Paesmans, Marianne
    Sculier, Jean-Paul
    Meert, Anne-Pascale
    ANTICANCER RESEARCH, 2011, 31 (01) : 281 - 285
  • [48] COMPLET RESPONSE DESPITE A VISIBLE TUMOR MASS IN NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH ERLOTINIB
    Weber, Britta
    Sorensen, Boe S.
    Knap, M. M.
    Madsen, H. H.
    Nexo, Ebba
    Meldgaard, Peter
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1466 - S1466
  • [49] High-throughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer
    Leidinger, Petra
    Brefort, Thomas
    Backes, Christina
    Krapp, Medea
    Galata, Valentina
    Beier, Markus
    Kohlhaas, Jochen
    Huwer, Hanno
    Meese, Eckart
    Keller, Andreas
    ONCOTARGET, 2016, 7 (04) : 4611 - 4623
  • [50] Predictive factors in patients with EGFR mutation-negative non-small cell lung cancer treated with erlotinib
    Ishii, Hidenobu
    Azuma, Koichi
    Yamada, Kazuhiko
    Kinoshita, Takashi
    Imamura, Youhei
    Hoshino, Tomoaki
    ONCOLOGY LETTERS, 2014, 8 (06) : 2699 - 2704
12345